查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2067658

北美和歐洲感染疾病分子診斷市場規模、佔有率和趨勢分析報告：按應用、檢測類別、客戶類型和細分市場預測（2026-2033 年）

North America & Europe Infectious Disease Molecular Diagnostics Market Size, Share & Trends Analysis Report By Application, By Test Category, By Customer Type, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

北美和歐洲感染疾病分子診斷市場概述

預計到 2025 年，北美和歐洲感染疾病分子診斷市場規模將達到 60.9 億美元，到 2033 年將達到 107.7 億美元，2026 年至 2033 年的複合年成長率為 7.44%。

呼吸道感染疾病、愛滋病毒和醫院感染等感染疾病的負擔日益加重，推動了這個市場的發展，加速了對快速準確診斷解決方案的需求。

此外，PCR、多重檢測和次世代定序等分子技術的不斷進步，以及強大的醫療保健基礎設施和政府對疾病監測和早期檢測系統的投資，也推動了市場成長。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：北美和歐洲感染疾病分子診斷市場：變數、趨勢和範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：北美和歐洲感染疾病分子診斷市場：按應用分類的商業分析

  • 按應用領域分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按應用領域分類，2021-2033年
  • 胃腸道感染疾病
  • 呼吸道傳染病檢查
  • 院內感染（HAI）
  • 血液感染疾病
  • 腦膜炎/中樞神經系統感染疾病
  • 媒介性行為感染感染

第5章：北美和歐洲感染疾病分子診斷市場：按檢測類別分類的商業分析

  • 按測試類型分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按測試類型分類，2021-2033 年
  • 症候群特異性檢測
  • 針對性檢測
  • 即時分子診斷

第6章：北美和歐洲感染疾病分子診斷市場：依客戶類型分析

  • 基於客戶類型的波動分析
  • 按客戶類型分類的市場估算與預測
  • 醫院實驗室
  • 參考實驗室
  • 學術機構
  • 當地醫院
  • 兒童醫院
  • 其他

第7章：北美和歐洲感染疾病分子診斷市場：按醫療機構分類的分析

  • 透過設定進行方差分析
  • 市場估算與預測（按醫療保健機構分類）
  • 中心檢查室
  • 靠近病患的醫療環境

第8章：北美和歐洲感染疾病分子診斷市場：處理能力分析

  • 處理能力波動分析
  • 按加工能力分類的市場估計與預測
  • 檢測數量較少的檢查室
  • 中型檢查室
  • 高容量檢測實驗室

第9章：北美和歐洲感染疾病分子診斷市場：演算法分析

  • 基於演算法的波動分析
  • 市場估算與預測（透過演算法）
  • 篩檢
  • 反射/演算法主導測試
  • 症候群特異性檢測（基於演算法）
  • 針對性確認測試

第10章：北美和歐洲感染疾病分子診斷市場：區域估計和趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威

第11章 競爭格局

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • BD
    • Diasorin SPA
    • Abbott
    • QuidelOrtho Corporation
    • Danaher Corporation
    • Thermo Fisher Scientific Inc
    • Biomerieux SA
    • F. Hoffmann-La Roche Ltd.
    • QIAGEN
    • Seegene Inc.
    • Bosch Healthcare Solutions GmbH.
    • QuidelOrtho Corporation
    • Hologic, Inc.
    • Siemens Healthineers AG
Product Code: GVR-4-68040-913-8

North America & Europe Infectious Disease Molecular Diagnostics Market Summary

The North America & Europe infectious disease molecular diagnostics market size was estimated at USD 6.09 billion in 2025 and is projected to reach USD 10.77 billion by 2033, growing at a CAGR of 7.44% from 2026 to 2033. The market is driven by the increasing burden of infectious diseases, including respiratory infections, HIV, and hospital-acquired infections, which is accelerating demand for rapid and highly accurate diagnostic solutions.

Growth is further supported by continuous advancements in molecular technologies such as PCR, multiplex assays, and next-generation sequencing, along with strong healthcare infrastructure and government investments in disease surveillance and early detection systems.

North America & Europe Infectious Disease Molecular Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the North America & Europe infectious disease molecular diagnostics market on the basis of test category, application customer type, setting-based, throughput, algorithm-based, region:

  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Gastrointestinal Infections
    • Syndromic Test
    • Targeted Test
    • Point of Care Molecular Diagnostics
  • Respiratory Infection Testing
    • Syndromic Test
    • Targeted Test
    • Point of Care Molecular Diagnostics
  • Hospital-Acquired Infections (HAIs)
    • Disease Type
    • Methicillin-Resistant Staphylococcus Aureus (MRSA)
    • Clostridioides difficile Infection (CDI)
    • Carbapenem-Resistant Enterobacteriaceae (CRE)
    • Vancomycin-Resistant Enterococci (VRE)
    • Other Nosocomial Pathogens
    • Test Category
    • Syndromic Test
    • Targeted Test
    • Point of Care Molecular Diagnostics
  • Bloodstream Infections
    • Syndromic Test
    • Targeted Test
    • Point of Care Molecular Diagnostics
  • Meningitis / CNS Infections
  • Vector-Borne Infections
    • Disease Type
    • Dengue
    • Zika
    • Lyme Disease
    • West Nile Virus
    • Chikungunya
    • Other Vector-Borne Infections
  • Test Category Outlook (Revenue, USD Million, 2021 - 2033)
  • Syndromic Test
  • Targeted Test
  • Point of Care Molecular Diagnostics
  • Customer Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Laboratories
  • Reference Laboratories
  • Academic Centers
  • Regional Hospitals
  • Children's Hospital
  • Other
  • Setting-Based Outlook (Revenue, USD Million, 2021 - 2033)
  • Central Laboratories
  • Near-Patient Settings
  • Throughput Outlook (Revenue, USD Million, 2021 - 2033)
  • Low-volume Laboratories
  • Mid-volume Laboratories
  • High-volume Laboratories
  • Algorithm-based Outlook (Revenue, USD Million, 2021 - 2033)
  • Frontline Screening
  • Reflex/Algorithm-driven Testing
  • Syndromic Testing
  • Targeted Confirmation
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. Test Category
    • 1.2.3. Customer Type
    • 1.2.4. Setting-based
    • 1.2.5. Throughput
    • 1.2.6. Algorithm-based
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. North America and Europe Infectious Disease Molecular Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising burden of infectious diseases & antimicrobial resistance (amr)
      • 3.2.1.2. Rapid adoption of syndromic molecular testing
      • 3.2.1.3. Shift toward decentralized & near-patient testing
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of molecular testing & infrastructure dependence
      • 3.2.2.2. Stringent and evolving regulatory requirements (FDA & IVDR impact)
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. North America and Europe Infectious Disease Molecular Diagnostics Market: Application Business Analysis

  • 4.1. Application Market Share, 2025 & 2033
  • 4.2. Application Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 4.4. Gastrointestinal Infections
    • 4.4.1. Gastrointestinal Infections Market, 2021 - 2033 (USD Million)
      • 4.4.1.1. Test Category
        • 4.4.1.1.1. Test Category Market, 2021 - 2033 (USD Million)
          • 4.4.1.1.1.1. Syndromic Test
            • 4.4.1.1.1.1.1. Syndromic Test Market, 2021 - 2033 (USD Million)
          • 4.4.1.1.1.2. Targeted Test
            • 4.4.1.1.1.2.1. Targeted Test Market, 2021 - 2033 (USD Million)
          • 4.4.1.1.1.3. Point of Care Molecular Diagnostics
            • 4.4.1.1.1.3.1. Point of Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • 4.5. Respiratory Infection Testing
    • 4.5.1. Respiratory Infection Testing Market, 2021 - 2033 (USD Million)
      • 4.5.1.1. Test Category
        • 4.5.1.1.1. Test Category Market, 2021 - 2033 (USD Million)
          • 4.5.1.1.1.1. Syndromic Test
            • 4.5.1.1.1.1.1. Syndromic Test Market, 2021 - 2033 (USD Million)
          • 4.5.1.1.1.2. Targeted Test
            • 4.5.1.1.1.2.1. Targeted Test Market, 2021 - 2033 (USD Million)
          • 4.5.1.1.1.3. Point of Care Molecular Diagnostics
            • 4.5.1.1.1.3.1. Point of Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • 4.6. Hospital-Acquired Infections (HAIs)
    • 4.6.1. Hospital-Acquired Infections (HAIs) Market, 2021 - 2033 (USD Million)
      • 4.6.1.1. Disease Type
        • 4.6.1.1.1. Disease Type Market, 2021 - 2033 (USD Million)
          • 4.6.1.1.1.1. Methicillin-Resistant Staphylococcus Aureus (MRSA)
            • 4.6.1.1.1.1.1. Methicillin-Resistant Staphylococcus Aureus (MRSA) Market, 2021 - 2033 (USD Million)
          • 4.6.1.1.1.2. Clostridioides Difficile Infection (CDI)
            • 4.6.1.1.1.2.1. Clostridioides difficile Infection (CDI) Market, 2021 - 2033 (USD Million)
          • 4.6.1.1.1.3. Carbapenem-Resistant Enterobacteriaceae (CRE)
            • 4.6.1.1.1.3.1. Carbapenem-Resistant Enterobacteriaceae (CRE) Market, 2021 - 2033 (USD Million)
          • 4.6.1.1.1.4. Vancomycin-Resistant Enterococci (VRE)
            • 4.6.1.1.1.4.1. Vancomycin-Resistant Enterococci (VRE) Market, 2021 - 2033 (USD Million)
          • 4.6.1.1.1.5. Other Nosocomial Pathogens
            • 4.6.1.1.1.5.1. Other Nosocomial Pathogens Market, 2021 - 2033 (USD Million)
      • 4.6.1.2. Test Category
        • 4.6.1.2.1. Test Category Market, 2021 - 2033 (USD Million)
          • 4.6.1.2.1.1. Syndromic Test
            • 4.6.1.2.1.1.1. Syndromic Test Market, 2021 - 2033 (USD Million)
          • 4.6.1.2.1.2. Targeted Test
            • 4.6.1.2.1.2.1. Targeted Test Market, 2021 - 2033 (USD Million)
          • 4.6.1.2.1.3. Point of Care Molecular Diagnostics
            • 4.6.1.2.1.3.1. Point of Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • 4.7. Bloodstream Infections
    • 4.7.1. Bloodstream Infections Market, 2021 - 2033 (USD Million)
      • 4.7.1.1. Test Category
        • 4.7.1.1.1. Test Category Market, 2021 - 2033 (USD Million)
          • 4.7.1.1.1.1. Syndromic Test
            • 4.7.1.1.1.1.1. Syndromic Test Market, 2021 - 2033 (USD Million)
          • 4.7.1.1.1.2. Targeted Test
            • 4.7.1.1.1.2.1. Targeted Test Market, 2021 - 2033 (USD Million)
          • 4.7.1.1.1.3. Point of Care Molecular Diagnostics
            • 4.7.1.1.1.3.1. Point of Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • 4.8. Meningitis / CNS Infections
    • 4.8.1. Meningitis / CNS Infections Market, 2021 - 2033 (USD Million)
  • 4.9. Vector-Borne Infections
    • 4.9.1. Vector-Borne Infections Market, 2021 - 2033 (USD Million)
      • 4.9.1.1. Disease Type
        • 4.9.1.1.1. Disease Type Market, 2021 - 2033 (USD Million)
          • 4.9.1.1.1.1. Dengue
            • 4.9.1.1.1.1.1. Dengue Market, 2021 - 2033 (USD Million)
          • 4.9.1.1.1.2. Zika
            • 4.9.1.1.1.2.1. Zika Market, 2021 - 2033 (USD Million)
          • 4.9.1.1.1.3. Lyme Disease
            • 4.9.1.1.1.3.1. Lyme Disease Market, 2021 - 2033 (USD Million)
          • 4.9.1.1.1.4. West Nile Virus
            • 4.9.1.1.1.4.1. West Nile Virus Market, 2021 - 2033 (USD Million)
          • 4.9.1.1.1.5. Chikungunya
            • 4.9.1.1.1.5.1. Chikungunya Market, 2021 - 2033 (USD Million)
          • 4.9.1.1.1.6. Other Vector-Borne Infections
            • 4.9.1.1.1.6.1. Other Vector-Borne Infections Market, 2021 - 2033 (USD Million)

Chapter 5. North America and Europe Infectious Disease Molecular Diagnostics Market: Test Category Business Analysis

  • 5.1. Test Type Market Share, 2025 & 2033
  • 5.2. Test Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Test Type, 2021 to 2033 (USD Million)
  • 5.4. Syndromic Testing
    • 5.4.1. Syndromic Testing Market, 2021 - 2033 (USD Million)
  • 5.5. Targeted Test
    • 5.5.1. Targeted In-Lab Testing Market, 2021 - 2033 (USD Million)
  • 5.6. Point of Care Molecular Diagnostics
    • 5.6.1. Point of Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)

Chapter 6. North America and Europe Infectious Disease Molecular Diagnostics Market: Customer Type Analysis

  • 6.1. Customer Type Movement Analysis
  • 6.2. Market Estimates & Forecast, by Customer Type (USD Million)
  • 6.3. Hospital Laboratories
    • 6.3.1. Hospital Laboratories Market, 2021 - 2033 (USD Million)
  • 6.4. Reference Laboratories
    • 6.4.1. Reference Laboratories Market, 2021 - 2033 (USD Million)
  • 6.5. Academic Centers
    • 6.5.1. Academic Centers Market, 2021 - 2033 (USD Million)
  • 6.6. Regional Hospitals
    • 6.6.1. Regional Hospitals Market, 2021 - 2033 (USD Million)
  • 6.7. Children's Hospital
    • 6.7.1. Children's Hospital Market, 2021 - 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. North America and Europe Infectious Disease Molecular Diagnostics Market Setting-Based Analysis

  • 7.1. Setting-Based Movement Analysis
  • 7.2. Market Estimates & Forecast, by Setting-Based (USD Million)
  • 7.3. Central Laboratories
    • 7.3.1. Central Laboratories Market, 2021 - 2033 (USD Million)
  • 7.4. Near-Patient Settings
    • 7.4.1. Near-Patient Settings Market, 2021 - 2033 (USD Million)

Chapter 8. North America and Europe Infectious Disease Molecular Diagnostics Market: Throughput Analysis

  • 8.1. Throughput Movement Analysis
  • 8.2. Market Estimates & Forecast, by Throughput (USD Million)
  • 8.3. Low-Volume Laboratories
    • 8.3.1. Low-Volume Laboratories Market, 2021 - 2033 (USD Million)
  • 8.4. Mid-Volume Laboratories
    • 8.4.1. Mid-Volume Laboratories Market, 2021 - 2033 (USD Million)
  • 8.5. High-Volume Laboratories
    • 8.5.1. High-Volume Laboratories Market, 2021 - 2033 (USD Million)

Chapter 9. North America and Europe Infectious Disease Molecular Diagnostics Market Algorithm-Based Analysis

  • 9.1. Algorithm-Based Movement Analysis
  • 9.2. Market Estimates & Forecast, by Algorithm-Based (USD Million)
  • 9.3. Frontline Screening
    • 9.3.1. Frontline Screening Market, 2021 - 2033 (USD Million)
  • 9.4. Reflex/Algorithm-Driven Testing
    • 9.4.1. Reflex/Algorithm-Driven Testing Market, 2021 - 2033 (USD Million)
  • 9.5. Syndromic Testing (Algorithm-Based)
    • 9.5.1. Syndromic Testing (Algorithm-Based) Market, 2021 - 2033 (USD Million)
  • 9.6. Targeted Confirmation
    • 9.6.1. Targeted Confirmation Market, 2021 - 2033 (USD Million)

Chapter 10. North America and Europe Infectious Disease Molecular Diagnostics Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Market Share Analysis, 2025 & 2033
  • 10.2. Regional Market Dashboard
  • 10.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 10.4. North America
    • 10.4.1. North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 10.4.2. U.S.
      • 10.4.2.1. Key Country Dynamics
      • 10.4.2.2. Target Disease Prevalence
      • 10.4.2.3. Regulatory Framework
      • 10.4.2.4. Reimbursement Framework
      • 10.4.2.5. U.S. North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.4.3. Canada
      • 10.4.3.1. Key Country Dynamics
      • 10.4.3.2. Target Disease Prevalence
      • 10.4.3.3. Regulatory Framework
      • 10.4.3.4. Reimbursement Framework
      • 10.4.3.5. Canada North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.4.4. Mexico
      • 10.4.4.1. Key Country Dynamics
      • 10.4.4.2. Target Disease Prevalence
      • 10.4.4.3. Regulatory Framework
      • 10.4.4.4. Reimbursement Framework
      • 10.4.4.5. Mexico North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5. Europe
    • 10.5.1. Europe North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.5.2. UK
      • 10.5.2.1. Key Country Dynamics
      • 10.5.2.2. Target Disease Prevalence
      • 10.5.2.3. Regulatory Framework
      • 10.5.2.4. Reimbursement Framework
      • 10.5.2.5. Uk North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.5.3. Germany
      • 10.5.3.1. Key Country Dynamics
      • 10.5.3.2. Target Disease Prevalence
      • 10.5.3.3. Regulatory Framework
      • 10.5.3.4. Reimbursement Framework
      • 10.5.3.5. Germany North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.5.4. France
      • 10.5.4.1. Key Country Dynamics
      • 10.5.4.2. Target Disease Prevalence
      • 10.5.4.3. Regulatory Framework
      • 10.5.4.4. Reimbursement Framework
      • 10.5.4.5. France North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.5.5. Italy
      • 10.5.5.1. Key Country Dynamics
      • 10.5.5.2. Target Disease Prevalence
      • 10.5.5.3. Regulatory Framework
      • 10.5.5.4. Reimbursement Framework
      • 10.5.5.5. Italy North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.5.6. Spain
      • 10.5.6.1. Key Country Dynamics
      • 10.5.6.2. Target Disease Prevalence
      • 10.5.6.3. Regulatory Framework
      • 10.5.6.4. Reimbursement Framework
      • 10.5.6.5. Spain North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.5.7. Denmark
      • 10.5.7.1. Key Country Dynamics
      • 10.5.7.2. Target Disease Prevalence
      • 10.5.7.3. Regulatory Framework
      • 10.5.7.4. Reimbursement Framework
      • 10.5.7.5. Denmark North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.5.8. Sweden
      • 10.5.8.1. Key Country Dynamics
      • 10.5.8.2. Target Disease Prevalence
      • 10.5.8.3. Regulatory Framework
      • 10.5.8.4. Reimbursement Framework
      • 10.5.8.5. Sweden North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.5.9. Norway
      • 10.5.9.1. Key Country Dynamics
      • 10.5.9.2. Target Disease Prevalence
      • 10.5.9.3. Regulatory Framework
      • 10.5.9.4. Reimbursement Framework
      • 10.5.9.5. Norway North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Participant Overview
  • 11.2. Company Market Position Analysis
  • 11.3. Company Categorization
  • 11.4. Strategy Mapping
  • 11.5. Company Profiles/Listing
    • 11.5.1. BD
      • 11.5.1.1. Overview
      • 11.5.1.2. Financial Performance
      • 11.5.1.3. Product Benchmarking
      • 11.5.1.4. Strategic Initiatives
    • 11.5.2. Diasorin S.P.A.
      • 11.5.2.1. Overview
      • 11.5.2.2. Financial Performance
      • 11.5.2.3. Product Benchmarking
      • 11.5.2.4. Strategic Initiatives
    • 11.5.3. Abbott
      • 11.5.3.1. Overview
      • 11.5.3.2. Financial Performance
      • 11.5.3.3. Product Benchmarking
      • 11.5.3.4. Strategic Initiatives
    • 11.5.4. QuidelOrtho Corporation
      • 11.5.4.1. Overview
      • 11.5.4.2. Financial Performance
      • 11.5.4.3. Product Benchmarking
      • 11.5.4.4. Strategic Initiatives
    • 11.5.5. Danaher Corporation
      • 11.5.5.1. Overview
      • 11.5.5.2. Financial Performance
      • 11.5.5.3. Product Benchmarking
      • 11.5.5.4. Strategic Initiatives
    • 11.5.6. Thermo Fisher Scientific Inc
      • 11.5.6.1. Overview
      • 11.5.6.2. Financial Performance
      • 11.5.6.3. Product Benchmarking
      • 11.5.6.4. Strategic Initiatives
    • 11.5.7. Biomerieux SA
      • 11.5.7.1. Overview
      • 11.5.7.2. Financial Performance
      • 11.5.7.3. Product Benchmarking
      • 11.5.7.4. Strategic Initiatives
    • 11.5.8. F. Hoffmann-La Roche Ltd.
      • 11.5.8.1. Overview
      • 11.5.8.2. Financial Performance
      • 11.5.8.3. Product Benchmarking
      • 11.5.8.4. Strategic Initiatives
    • 11.5.9. QIAGEN
      • 11.5.9.1. Overview
      • 11.5.9.2. Financial Performance
      • 11.5.9.3. Product Benchmarking
      • 11.5.9.4. Strategic Initiatives
    • 11.5.10. Seegene Inc.
      • 11.5.10.1. Overview
      • 11.5.10.2. Financial Performance
      • 11.5.10.3. Product Benchmarking
      • 11.5.10.4. Strategic Initiatives
    • 11.5.11. Bosch Healthcare Solutions GmbH.
      • 11.5.11.1. Overview
      • 11.5.11.2. Financial Performance
      • 11.5.11.3. Product Benchmarking
      • 11.5.11.4. Strategic Initiatives
    • 11.5.12. QuidelOrtho Corporation
      • 11.5.12.1. Overview
      • 11.5.12.2. Financial Performance
      • 11.5.12.3. Product Benchmarking
      • 11.5.12.4. Strategic Initiatives
    • 11.5.13. Hologic, Inc.
      • 11.5.13.1. Overview
      • 11.5.13.2. Financial Performance
      • 11.5.13.3. Product Benchmarking
      • 11.5.13.4. Strategic Initiatives
    • 11.5.14. Siemens Healthineers AG
      • 11.5.14.1. Overview
      • 11.5.14.2. Financial Performance
      • 11.5.14.3. Product Benchmarking
      • 11.5.14.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 North America Infectious Disease Molecular Diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 4 North America Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
  • Table 5 North America Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
  • Table 6 North America Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
  • Table 7 North America Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
  • Table 8 North America Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
  • Table 9 North America Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
  • Table 10 U.S. Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
  • Table 11 U.S. Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
  • Table 12 U.S. Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
  • Table 13 U.S. Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
  • Table 14 U.S. Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
  • Table 15 U.S. Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
  • Table 16 Canada Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
  • Table 17 Canada Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
  • Table 18 Canada Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
  • Table 19 Canada Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
  • Table 20 Canada Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
  • Table 21 Canada Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
  • Table 22 Mexico Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
  • Table 23 Mexico Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
  • Table 24 Mexico Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
  • Table 25 Mexico Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
  • Table 26 Mexico Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
  • Table 27 Mexico Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
  • Table 28 Europe Infectious Disease Molecular Diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 29 Europe Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
  • Table 30 Europe Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
  • Table 31 Europe Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
  • Table 32 Europe Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
  • Table 33 Europe Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
  • Table 34 Europe Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
  • Table 35 UK Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
  • Table 36 UK Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
  • Table 37 UK Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
  • Table 38 UK Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
  • Table 39 UK Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
  • Table 40 UK Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
  • Table 41 Germany Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
  • Table 42 Germany Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
  • Table 43 Germany Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
  • Table 44 Germany Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
  • Table 45 Germany Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
  • Table 46 Germany Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
  • Table 47 France Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
  • Table 48 France Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
  • Table 49 France Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
  • Table 50 France Infectious Disease Molecular Diagnostics market, by Setting-based, 2021 - 2033 (USD Million)
  • Table 51 France Infectious Disease Molecular Diagnostics market, by Throughput, 2021 - 2033 (USD Million)
  • Table 52 France Infectious Disease Molecular Diagnostics market by Algorithm-based, 2021 - 2033 (USD Million)
  • Table 53 Italy Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
  • Table 54 Italy North America and Europe Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
  • Table 55 Italy Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
  • Table 56 Italy Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
  • Table 57 Italy Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
  • Table 58 Italy Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
  • Table 59 Spain Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
  • Table 60 Spain Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
  • Table 61 Spain Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
  • Table 62 Spain Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
  • Table 63 Spain Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
  • Table 64 Spain Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
  • Table 65 Norway Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
  • Table 66 Norway Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
  • Table 67 Norway Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
  • Table 68 Norway Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
  • Table 69 Norway Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
  • Table 70 Norway Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
  • Table 71 Denmark Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
  • Table 72 Denmark Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
  • Table 73 Denmark Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
  • Table 74 Denmark Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
  • Table 75 Denmark Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
  • Table 76 Denmark Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)
  • Table 77 Sweden Infectious Disease Molecular Diagnostics market, by Application, 2021 - 2033 (USD Million)
  • Table 78 Sweden Infectious Disease Molecular Diagnostics market, by Test Category, 2021 - 2033 (USD Million)
  • Table 79 Sweden Infectious Disease Molecular Diagnostics market, by Customer Type, 2021 - 2033 (USD Million)
  • Table 80 Sweden Infectious Disease Molecular Diagnostics market Setting-based, 2021 - 2033 (USD Million)
  • Table 81 Sweden Infectious Disease Molecular Diagnostics market Throughput, 2021 - 2033 (USD Million)
  • Table 82 Sweden Infectious Disease Molecular Diagnostics market Algorithm-based, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 North America and Europe Infectious Disease Molecular Diagnostics segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Application and test category snapshot
  • Fig. 11 Customer type and setting-based snapshot
  • Fig. 12 Throughput and algorithm snapshot
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Market trends & outlook
  • Fig. 15 U.S. seasonal infectious disease burden data (in '000), 2021-2026
  • Fig. 16 Heat map showing the detection frequency (%) of microbial target categories across the four BioFire FilmArray panels evaluated in this study (BCID2, PN Plus, ME and GI)
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 North America and Europe infectious disease molecular diagnostics market: Application outlook and key takeaways
  • Fig. 20 North America and Europe infectious disease molecular diagnostics market: Application movement analysis
  • Fig. 21 Gastrointestinal infections market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Syndromic test market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Targeted test market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Point of care molecular diagnostics test market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Respiratory infection testing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 Syndromic test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 27 Targeted test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 28 Point of care molecular diagnostics test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 29 Hospital-acquired infections (HAIs) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 30 Methicillin-Resistant Staphylococcus aureus (MRSA) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 31 Clostridioides difficile Infection (CDI) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 32 Carbapenem-Resistant Enterobacteriaceae (CRE) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 33 Vancomycin-Resistant Enterococci (VRE) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 34 Other Nosocomial Pathogens market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 35 Syndromic test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 36 Targeted test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 37 Point of care molecular diagnostics test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 38 Bloodstream infections market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 39 Syndromic test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 40 Targeted test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 41 Point of care molecular diagnostics test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 42 Meningitis/ CNS infections market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 43 Vector-borne infections market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 44 Dengue market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 45 Zika market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 46 Lyme Disease market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 47 West Nile Virus market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 48 Chikungunya market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 49 Other Vector-Borne Infections market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 50 North America and Europe infectious disease molecular diagnostics market: test category outlook and key takeaways
  • Fig. 51 North America and Europe infectious disease molecular diagnostics market: test category movement analysis
  • Fig. 52 Syndromic testing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 53 Targeted in-lab testing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 54 Point-of-Care (PoC) testing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 55 North America and Europe infectious disease molecular diagnostics market: customer type outlook and key takeaways
  • Fig. 56 North America and Europe infectious disease molecular diagnostics market: customer type movement analysis
  • Fig. 57 Hospital laboratories market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 58 Reference laboratories market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 59 Academic centres market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 60 Regional hospitals market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 61 Children's hospitals market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 62 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 63 North America and Europe infectious disease molecular diagnostics market: setting-based outlook and key takeaways
  • Fig. 64 North America and Europe infectious disease molecular diagnostics market: setting-based movement analysis
  • Fig. 65 Central laboratories market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 66 Near-patient settings market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 67 North America and Europe infectious disease molecular diagnostics market: throughput outlook and key takeaways
  • Fig. 68 North America and Europe Infectious Disease Molecular Diagnostics market: throughput movement analysis
  • Fig. 69 Low-volume laboratories market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 70 Mid-volume laboratories market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 71 High-volume laboratories market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 72 North America and Europe infectious disease molecular diagnostics market: Algorithm-based outlook and key takeaways
  • Fig. 73 North America and Europe Infectious Disease Molecular Diagnostics market: algorithm-based movement analysis
  • Fig. 74 Frontline screening market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 75 Reflex/algorithm-driven testing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 76 Syndromic testing (algorithm-based) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 77 Targeted confirmation market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 78 North America and Europe infectious disease molecular diagnostics market revenue, by region, 2025 & 2033 (USD Million)
  • Fig. 79 Regional market place: Key takeaways
  • Fig. 80 North America infectious disease molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 U.S. infectious disease molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 Canada infectious disease molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 85 Mexico infectious disease molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Rest of the Europe infectious disease molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 87 Key company categorization
  • Fig. 88 Company market share, 2025
  • Fig. 89 Strategy mapping